Lumida
/SGRY
⌘K
Surgery Partners Inc

Surgery Partners Inc

SGRY
$14.38USD+1.84%+0.26 today

MARKET CAP

1.9B

P/E (TTM)

FWD P/E

DAY RANGE

$14 – $15

52W RANGE

$11
$23

AI Summary

Stalk
StalkMedium

Despite a persistent long-term downtrend and price below key moving averages, the chart’s Bearish Exhaustion pattern in an oversold context grants a medium-term bullish mean-reversion bias. Short-term execution lacks clear entry while price consolidates around the 9/20 EMAs, warranting patience and stalking pullbacks into the $13.80–$14.00 support zone ahead of a potential reversal bounce.

  • Analysts rate SGRY Moderate Buy with $19.45 PT, implying +37.8% upside
  • High earnings yield (~57%) suggests attractive valuation
  • Weak profitability metrics highlight margin and cash flow concerns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.2B$2.5B$2.7B$3.1B$3.3B
YoY %+19.6%+14.1%+8.0%+13.5%+6.2%
P / Sales1.7x1.0x1.4x0.9x0.6x
EV / Sales3.3x2.2x2.7x2.1x1.9x
Gross Profit, Adj.$2.2B$2.5B$2.7B$3.1B$3.3B
YoY %+19.6%+14.1%+8.0%+13.5%+6.2%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit3.3x2.2x2.7x2.1x1.9x
EBITDA, Adj.$425.3M$472.7M$534.1M$626.9M$655.5M
YoY %+29.3%+11.1%+13.0%+17.4%+4.6%
Margin %19.1%18.6%19.5%20.1%19.8%
EV / EBITDA17.2x11.7x13.7x10.6x9.6x
EBIT$286.7M$339.7M$328.2M$369.9M$397.0M
YoY %+62.7%+18.5%-3.4%+12.7%+7.3%
Margin %12.9%13.4%12.0%11.9%12.0%
EV / EBIT25.4x16.3x22.2x18.0x15.9x
Net Income$-81.2M$-54.6M$-11.9M$-168.1M$-77.9M
YoY %+47.8%+32.8%+78.2%-1312.6%+53.7%
Net Margin-3.6%-2.2%-0.4%-5.4%-2.4%
EPS (GAAP)-$1.12-$0.59-$0.09-$1.33-$0.61
YoY %+64.9%+47.3%+84.7%-1377.8%+54.1%